Who are APVAC2 vaccine plus Poly-ICLC and GM-CSF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LI, AScVS + Prazosin, HyperAcute-Pancreas Immunotherapy, IMM-101.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apvac2-vaccine-plus-poly-iclc-and-gm-csf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

APVAC2 vaccine plus Poly-ICLC and GM-CSF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APVAC2 vaccine plus Poly-ICLC and GM-CSF (APVAC2 vaccine plus Poly-ICLC and GM-CSF) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cancer immunotherapy. Area: Oncology.

phase 1 Cancer immunotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

APVAC2 vaccine plus Poly-ICLC and GM-CSF (APVAC2 vaccine plus Poly-ICLC and GM-CSF) — Immatics Biotechnologies GmbH. APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
APVAC2 vaccine plus Poly-ICLC and GM-CSF TARGET	APVAC2 vaccine plus Poly-ICLC and GM-CSF	Immatics Biotechnologies GmbH	phase 1	Cancer immunotherapy
LI	LI	CEL-SCI Corporation	marketed	Cancer immunotherapy vaccine
AScVS + Prazosin	AScVS + Prazosin	Haffkine Bio-Pharmaceutical Corporation Ltd.	phase 3	Cancer immunotherapy vaccine
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
IMM-101	IMM-101	Immodulon Therapeutics Ltd	phase 3	Cancer immunotherapy vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cancer immunotherapy class)

Immatics Biotechnologies GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APVAC2 vaccine plus Poly-ICLC and GM-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/apvac2-vaccine-plus-poly-iclc-and-gm-csf. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab